Role of contrast enhanced breast MRI in diagnosis of breast lesions

CHF 70.20
Auf Lager
SKU
ACILKJIERUP
Stock 1 Verfügbar
Geliefert zwischen Mi., 26.11.2025 und Do., 27.11.2025

Details

Objective: The objective of our study was to evaluate how to categorize breast lesions detected at contrast-enhanced breast MRI in accordance with the imaging findings and the indication for MRI. Subjects and methods: This study included 50 patients, their ages ranged from 18- 70 years. MRI examination included conventional sequences and dynamic series. Morphological features and dynamic parameters were recorded with classification of the findings according to BI-RADS. The findings of each modality were correlated with histopathological results. Results: BIRADS 2, 3 were considered as benign lesions and BIRADS 4, 5 were considered as malignant. There were 17 benign lesions (34 %) and 33 malignant lesions (66 %). DCE-MRI proved to have sensitivity of 100 %, specificity of 70.6 %, PPV of 86.8 %, NPV of 100 % and accuracy of 90.0 %. Conclusion: Our study results indicate that DCE-MRI has high sensitivity and moderate specificity in differentiation between benign and malignant breast lesions.

Autorentext

DR.Mona Farrag Abd Elbaky, assisstant lecturer of radio diagnosis at Fayoum university hospital, Egypt.

Weitere Informationen

  • Allgemeine Informationen
    • Sprache Englisch
    • Autor Mona Farrag
    • Titel Role of contrast enhanced breast MRI in diagnosis of breast lesions
    • Veröffentlichung 07.01.2019
    • ISBN 6202359242
    • Format Kartonierter Einband
    • EAN 9786202359245
    • Jahr 2019
    • Größe H220mm x B150mm x T10mm
    • Gewicht 250g
    • Genre Medizin
    • Anzahl Seiten 156
    • Herausgeber Noor Publishing
    • GTIN 09786202359245

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470